Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, overvalued
Target Price
The average target price of 4565.T is 1905 and suggests 104% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell